Anamorelin Hydrochloride

Phase 2Small molecule

MM.D. Anderson Cancer Center

Anamorelin Hydrochloride is one of 12 small molecule programs targeting Anorexia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Physical ActivityActive, not recruiting

Physical ActivityPhase 2

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Physical Activity

#DrugCompanyPhaseTrials

Xolair

Roche

Approved

1 2

Hemlibra

Roche

Approved

—3

Ranexa

MMenarini International Operations Luxembourg SA

Approved

1 4

Nicorette

Pfizer

Preclinical

1 5

Taxol

Teva

Preclinical

1 6

Anamorelin Hydrochloride

MM.D. Anderson Cancer Center

Phase 2

1 7

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

1 8

Efanesoctocog Alfa

Sanofi

Preclinical

1 9

Immunotherapy

Bristol-Myers Squibb

Preclinical

—10

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalActive, not recruiting

Anorexia

NCT03637816

Clinical

Trials by Indication[1]

Bone1 trial

Effect of a Ghrelin Receptor Agonist on Muscle and Bone

Completed·TTufts University·Phase 1·NCT04021706·32 enrolled

Pancreatic Cancer1 trial

Anamorelin Study for Advanced Pancreatic Cancer

Terminated·LLahey Clinic·Phase 2·NCT04844970·4 enrolled

Physical Activity1 trial

Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03035409·129 enrolled

Cachexia; Cancer1 trial

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Completed·HHelsinn Healthcare SA·Phase 3·NCT03743051·318 enrolled

Anorexia1 trial

Qualitative Study on Experiences Related to Anorexia and the Effects of Anamorelin and Placebo in Advanced Non-Small-Cell Lung Cancer Patients With Anorexia-Cachexia: A Preliminary Study

Active, not recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT03637816·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Anamorelin Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anamorelin Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anamorelin Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MM.D. Anderson Cancer Center

Anamorelin Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Bone1 trial

Pancreatic Cancer1 trial

Physical Activity1 trial

Cachexia; Cancer1 trial

Anorexia1 trial

References

Drug Info

Quick Facts

Related News